Published in Cancer Res on January 01, 2008
Negative regulation of hypoxic responses via induced Reptin methylation. Mol Cell (2010) 1.68
Identification of rare cancer driver mutations by network reconstruction. Genome Res (2009) 1.47
Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A. Mol Cell Biol (2012) 1.26
Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med (2008) 1.08
Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene (2010) 1.08
Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization. Cancer Res (2012) 1.07
Ubc9 acetylation modulates distinct SUMO target modification and hypoxia response. EMBO J (2013) 0.99
Time-dependent stabilization of hypoxia inducible factor-1α by different intracellular sources of reactive oxygen species. PLoS One (2012) 0.98
Probing high affinity sequences of DNA aptamer against VEGF165. PLoS One (2012) 0.96
Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World J Gastroenterol (2012) 0.91
Tie2-dependent knockout of HIF-1 impairs burn wound vascularization and homing of bone marrow-derived angiogenic cells. Cardiovasc Res (2011) 0.86
Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells. BMC Cancer (2013) 0.84
The decrease of mineralcorticoid receptor drives angiogenic pathways in colorectal cancer. PLoS One (2013) 0.83
Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells. J Biol Chem (2010) 0.81
Association of the VEGFR2 gene His472Gln polymorphism with endurance-related phenotypes. Eur J Appl Physiol (2009) 0.80
Investigating the antiproliferative activity of high affinity DNA aptamer on cancer cells. PLoS One (2013) 0.78
Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells. Yonsei Med J (2013) 0.76
Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models. Dis Model Mech (2014) 0.75
Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. Sci Rep (2017) 0.75
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. Sci Rep (2017) 0.75
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med (2003) 3.71
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res (2002) 2.97
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res (2005) 2.49
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst (2011) 2.11
Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med (2009) 2.09
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res (2006) 2.07
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res (2011) 1.74
Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood (2005) 1.74
The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology (2006) 1.73
S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell (2011) 1.71
Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res (2004) 1.70
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther (2009) 1.67
Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc Natl Acad Sci U S A (2011) 1.45
Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J Med Chem (2002) 1.43
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol (2002) 1.40
The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol (2009) 1.39
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol (2012) 1.37
Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J (2002) 1.37
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells (2010) 1.35
Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol (2002) 1.34
Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine (2008) 1.34
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis (2007) 1.33
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer (2009) 1.32
Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res (2012) 1.32
DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A (2009) 1.30
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res (2007) 1.27
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin Cancer Res (2011) 1.22
Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer (2009) 1.20
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat (2009) 1.20
Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur J Cancer (2009) 1.19
Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res (2007) 1.17
Hypoxia potentiates glioma-mediated immunosuppression. PLoS One (2011) 1.17
Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine (2010) 1.13
New antitumor imidazo[2,1-b]thiazole guanylhydrazones and analogues. J Med Chem (2008) 1.12
Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther (2009) 1.11
Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur J Cancer (2002) 1.10
A high-throughput fluorescence-anisotropy screen that identifies small molecule inhibitors of the DNA binding of B-ZIP transcription factors. Anal Biochem (2005) 1.09
Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. Clin Cancer Res (2003) 1.07
Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion. Cancer Res (2010) 1.07
Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr Top Med Chem (2002) 1.05
Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells. Clin Cancer Res (2004) 1.04
Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia (2011) 1.02
Hypoxia selectively inhibits monocyte chemoattractant protein-1 production by macrophages. J Immunol (2004) 1.01
Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion. Oncogene (2005) 1.01
Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1. Cell Cycle (2006) 0.99
Induction of apoptosis in human cancer cells by candidaspongiolide, a novel sponge polyketide. J Natl Cancer Inst (2008) 0.98
Hypoxia: a double-edged sword of immunity. J Mol Med (Berl) (2011) 0.97
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer (2011) 0.97
Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS One (2012) 0.96
Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine (2010) 0.96
Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle (2004) 0.96
Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. J Virol (2005) 0.96
The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production. J Biol Chem (2013) 0.95
A novel antimicrobial indolizinium alkaloid from Aniba panurensis. J Nat Prod (2004) 0.95
Identification of HIV-1 nucleocapsid protein: nucleic acid antagonists with cellular anti-HIV activity. Biochem Biophys Res Commun (2002) 0.95
Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore. Bioorg Med Chem (2006) 0.95
Inhibitors of the NF-kappaB activation pathway from Cryptocarya rugulosa. J Nat Prod (2009) 0.95
Aspirochlorine class compounds from Aspergillus flavus inhibit azole-resistant Candida albicans. J Nat Prod (2005) 0.94
Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer. J Biol Chem (2013) 0.94
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer Chemother Pharmacol (2009) 0.94
Potential for therapeutic targeting of tumor stem cells. Cancer Sci (2009) 0.94
Efficient systemic expression of bioactive IL-15 in mice upon delivery of optimized DNA expression plasmids. DNA Cell Biol (2007) 0.93
Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads. Cell Cycle (2009) 0.93
Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy. J Pediatr Hematol Oncol (2009) 0.92
Synergystic induction of HIF-1alpha transcriptional activity by hypoxia and lipopolysaccharide in macrophages. Cell Cycle (2007) 0.92
Identification of a new natural camptothecin analogue in targeted screening for HIF-1alpha inhibitors. Planta Med (2007) 0.92
Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine (2010) 0.91
Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene (2003) 0.91
Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Sci (2009) 0.91
Identification of polymerase and processivity inhibitors of vaccinia DNA synthesis using a stepwise screening approach. Antiviral Res (2008) 0.91
A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay. Anal Biochem (2003) 0.91
Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. Mol Cancer (2014) 0.90
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors. Cancer Chemother Pharmacol (2013) 0.90
Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression. Mol Cancer Res (2007) 0.90
Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells. J Clin Invest (2013) 0.89
Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus. Antimicrob Agents Chemother (2005) 0.89
A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. J Exp Clin Cancer Res (2013) 0.89
"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies. Cancer Res (2003) 0.88
Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma. Int J Cancer (2002) 0.87
Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines. Biochem Pharmacol (2006) 0.87
Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. Mol Cancer Ther (2002) 0.87